Target Price | €11.62 |
Price | €9.55 |
Potential |
21.69%
register free of charge
|
Number of Estimates | 17 |
17 Analysts have issued a price target BBVA 2025 .
The average BBVA target price is €11.62.
This is
21.69%
register free of charge
€13.60
42.38%
register free of charge
€9.20
3.69%
register free of charge
|
|
A rating was issued by 19 analysts: 10 Analysts recommend BBVA to buy, 8 to hold and 1 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the BBVA stock has an average upside potential 2025 of
21.69%
register free of charge
|
Dec '23 |
2024 Estimates |
|
---|---|---|
Revenue Billion € | 63.77 | 34.33 |
40.36% | 46.16% | |
Net Margin | 11.66% | 27.27% |
7.17% | 133.90% |
13 Analysts have issued a sales forecast BBVA 2024 . The average BBVA sales estimate is
This results in the following potential growth metrics:
11 BBVA Analysts have issued a net profit forecast 2024. The average BBVA net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '23 |
2024 Estimates |
|
---|---|---|
Earnings Per Share € | 1.29 | 1.62 |
30.30% | 25.58% | |
P/E | 5.80 | |
EV/Sales | 3.36 |
11 Analysts have issued a BBVA forecast for earnings per share. The average BBVA <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the BBVA stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.